دورية أكاديمية
Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells.
العنوان: | Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. |
---|---|
المؤلفون: | Alcalá S; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM), CSIC-UAM, 28029 Madrid, Spain.; Department of Biochemistry, Universidad Autónoma de Madrid (UAM), 28029 Madrid, Spain.; Chronic Diseases and Cancer, Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain., Mayoral-Varo V; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM), CSIC-UAM, 28029 Madrid, Spain., Ruiz-Cañas L; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM), CSIC-UAM, 28029 Madrid, Spain.; Department of Biochemistry, Universidad Autónoma de Madrid (UAM), 28029 Madrid, Spain.; Chronic Diseases and Cancer, Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain., López-Gil JC; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM), CSIC-UAM, 28029 Madrid, Spain.; Department of Biochemistry, Universidad Autónoma de Madrid (UAM), 28029 Madrid, Spain.; Chronic Diseases and Cancer, Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain., Heeschen C; Stem Cells & Cancer Group, Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.; Present address: Center for Single-Cell Omics and Key Laboratory of Oncogenes and Related Genes, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, China., Martín-Pérez J; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM), CSIC-UAM, 28029 Madrid, Spain., Sainz B Jr; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM), CSIC-UAM, 28029 Madrid, Spain.; Department of Biochemistry, Universidad Autónoma de Madrid (UAM), 28029 Madrid, Spain.; Chronic Diseases and Cancer, Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain. |
المصدر: | International journal of molecular sciences [Int J Mol Sci] 2020 Oct 09; Vol. 21 (20). Date of Electronic Publication: 2020 Oct 09. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: PubMed not MEDLINE; MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI, [2000- |
مستخلص: | The proto-oncogene nonreceptor tyrosine-protein kinase SRC is a member of the SRC family of tyrosine kinases (SFKs), and its activation and overexpression have been shown to play a protumorigenic role in multiple solid cancers, including pancreatic ductal adenocarcinoma (PDAC). PDAC is currently the seventh-leading cause of cancer-related death worldwide, and, by 2030, it is predicted to become the second-leading cause of cancer-related death in the United States. PDAC is characterized by its high lethality (5-year survival of rate of <10%), invasiveness, and chemoresistance, all of which have been shown to be due to the presence of pancreatic cancer stem cells (PaCSCs) within the tumor. Due to the demonstrated overexpression of SRC in PDAC, we set out to determine if SRC kinases are important for PaCSC biology using pharmacological inhibitors of SRC kinases (dasatinib or PP2). Treatment of primary PDAC cultures established from patient-derived xenografts with dasatinib or PP2 reduced the clonogenic, self-renewal, and tumor-initiating capacity of PaCSCs, which we attribute to the downregulation of key signaling factors such as p-FAK, p-ERK1-2, and p-AKT. Therefore, this study not only validates that SRC kinases are relevant and biologically important for PaCSCs but also suggests that inhibitors of SRC kinases may represent a possible future treatment option for PDAC patients, although further studies are still needed. |
التعليقات: | Erratum in: Int J Mol Sci. 2020 Dec 03;21(23):. (PMID: 33287468) |
References: | Blood. 1999 Nov 15;94(10):3315-24. (PMID: 10552940) Oncogene. 2004 Sep 23;23(44):7378-90. (PMID: 15286700) PLoS One. 2012;7(3):e33414. (PMID: 22479394) Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647) Nature. 1978 Aug 10;274(5671):535-9. (PMID: 307692) PLoS One. 2020 Jul 16;15(7):e0235850. (PMID: 32673341) Clin Exp Metastasis. 2018 Oct;35(7):663-677. (PMID: 29987671) Cell Signal. 2012 Jun;24(6):1276-86. (PMID: 22570868) Nat Methods. 2014 Nov;11(11):1161-9. (PMID: 25262208) PLoS One. 2017 Nov 28;12(11):e0188637. (PMID: 29182685) J Immunol Methods. 2009 Aug 15;347(1-2):70-8. (PMID: 19567251) Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220. (PMID: 30718832) Pancreas. 2014 Jul;43(5):768-76. (PMID: 24763074) Biochem Biophys Res Commun. 2004 Apr 23;317(1):133-41. (PMID: 15047158) Gut. 2015 Dec;64(12):1921-35. (PMID: 25841238) Clin Cancer Res. 2004 Dec 1;10(23):8028-36. (PMID: 15585638) Oncotarget. 2017 Jun 16;8(31):51733-51747. (PMID: 28881682) Cell. 2006 Aug 25;126(4):663-76. (PMID: 16904174) Anticancer Agents Med Chem. 2017;17(10):1351-1356. (PMID: 28044939) Sci Rep. 2015 May 14;5:10194. (PMID: 25973915) Oncogene. 2017 Mar;36(11):1546-1558. (PMID: 27617576) Cancer Res. 2019 Nov 15;79(22):5702-5703. (PMID: 31772072) Tissue Eng Regen Med. 2016 Jun 9;13(3):261-269. (PMID: 30603407) Mol Cancer. 2012 Sep 25;11:73. (PMID: 23009336) Nat Med. 2017 Oct 6;23(10):1124-1134. (PMID: 28985214) Cell Mol Life Sci. 2004 Oct;61(19-20):2535-48. (PMID: 15526160) Cancers (Basel). 2020 Jul 04;12(7):. (PMID: 32635473) JAMA. 2019 Aug 6;322(5):438-444. (PMID: 31386141) BMC Cancer. 2016 Aug 12;16:632. (PMID: 27520560) Semin Cancer Biol. 2018 Dec;53:48-58. (PMID: 30130663) Nature. 2016 Mar 3;531(7592):47-52. (PMID: 26909576) Cancer Res. 2016 Aug 1;76(15):4546-58. (PMID: 27261509) Cancers (Basel). 2019 Jan 21;11(1):. (PMID: 30669703) Int Rev Cell Mol Biol. 2017;331:83-122. (PMID: 28325216) Nat Rev Dis Primers. 2016 Apr 21;2:16022. (PMID: 27158978) Nat Biotechnol. 2009 Jan;27(1):77-83. (PMID: 19098899) EBioMedicine. 2018 Mar;29:112-127. (PMID: 29433983) Cancers (Basel). 2020 May 23;12(5):. (PMID: 32456226) Cancer Lett. 2019 May 1;449:8-19. (PMID: 30673589) J Biol Chem. 2001 Aug 24;276(34):31858-62. (PMID: 11445557) Cancer Chemother Pharmacol. 2019 Jun;83(6):1025-1035. (PMID: 30895346) Biochem Biophys Res Commun. 1998 Feb 13;243(2):503-8. (PMID: 9480838) Cell. 2012 Jun 8;149(6):1284-97. (PMID: 22632761) Mol Cancer Ther. 2016 Aug;15(8):1952-63. (PMID: 27222538) Nat Genet. 2015 Oct;47(10):1168-78. (PMID: 26343385) Mol Cancer. 2015 Nov 21;14:199. (PMID: 26588899) Nat Chem Biol. 2010 Apr;6(4):291-9. (PMID: 20190765) Cell Stem Cell. 2019 Jan 3;24(1):25-40. (PMID: 30595497) Mol Cell Biol. 1994 Oct;14(10):6915-25. (PMID: 7935409) J Biol Chem. 1996 Jan 12;271(2):695-701. (PMID: 8557675) Semin Cancer Biol. 2018 Dec;53:223-231. (PMID: 30130664) Blood. 2008 Mar 1;111(5):2505-15. (PMID: 18299451) Mol Cancer Ther. 2014 Jul;13(7):1758-71. (PMID: 24785258) Gastroenterology. 2019 May;156(7):2073-2084. (PMID: 30716326) Gut. 2015 Dec;64(12):1936-48. (PMID: 25887381) Trends Pharmacol Sci. 2012 Mar;33(3):122-8. (PMID: 22153719) Mol Endocrinol. 2003 Nov;17(11):2268-82. (PMID: 12907754) Cell Metab. 2015 Oct 6;22(4):590-605. (PMID: 26365176) Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40. (PMID: 6930676) Cancer Lett. 2019 Aug 10;457:40-46. (PMID: 31078737) Cancer Control. 2000 Sep-Oct;7(5):421-7. (PMID: 11000611) Cell Stem Cell. 2007 Sep 13;1(3):313-23. (PMID: 18371365) Oncotarget. 2015 Nov 10;6(35):38029-45. (PMID: 26515729) Nat Med. 2011 Apr;17(4):500-3. (PMID: 21460848) Clin Cancer Res. 2018 Oct 1;24(19):4874-4886. (PMID: 29959144) Nat Med. 2018 Jul;24(7):954-960. (PMID: 29808009) Nature. 1994 Feb 17;367(6464):645-8. (PMID: 7509044) Mol Biol Rep. 2019 Dec;46(6):6629-6645. (PMID: 31486978) Nat Struct Mol Biol. 2008 Oct;15(10):1109-18. (PMID: 18794843) Br J Cancer. 2018 Dec;119(12):1495-1507. (PMID: 30482914) Cell. 2007 Jun 29;129(7):1261-74. (PMID: 17604717) Mol Cell Biol. 1997 Mar;17(3):1702-13. (PMID: 9032297) Mol Cancer Ther. 2010 Aug;9(8):2322-32. (PMID: 20682659) Clin Cancer Res. 2011 Apr 1;17(7):1713-21. (PMID: 21300758) Cancers (Basel). 2020 Jun 02;12(6):. (PMID: 32498343) Stem Cells Int. 2019 Jun 2;2019:8475389. (PMID: 31281387) Genes Dev. 1994 Sep 1;8(17):1999-2007. (PMID: 7958873) Gut. 2017 Sep;66(9):1665-1676. (PMID: 27325420) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) Genome Med. 2011 Nov 29;3(11):75. (PMID: 22126538) Cancer Res. 2016 Feb 15;76(4):927-39. (PMID: 26676753) Oncogene. 2008 Dec 4;27(57):7212-22. (PMID: 18794807) Gastroenterology. 2016 Dec;151(6):1218-1231. (PMID: 27578530) Mol Cell Biol. 1988 Oct;8(10):4541-6. (PMID: 2460746) Nat Commun. 2020 May 29;11(1):2682. (PMID: 32472071) J Med Chem. 2004 Dec 30;47(27):6658-61. (PMID: 15615512) Oncotarget. 2015 May 30;6(15):13520-38. (PMID: 25980494) Cancer Res. 2007 Feb 1;67(3):1030-7. (PMID: 17283135) Pancreas. 2019 Mar;48(3):329-334. (PMID: 30747824) J Biol Chem. 2016 Jul 22;291(30):15540-50. (PMID: 27226554) Int J Biol Sci. 2012;8(10):1385-97. (PMID: 23139636) Nat Rev Clin Oncol. 2009 Oct;6(10):587-95. (PMID: 19787002) Cell Stem Cell. 2011 Nov 4;9(5):433-46. (PMID: 22056140) Anal Biochem. 1987 Apr;162(1):156-9. (PMID: 2440339) Signal Transduct Target Ther. 2020 Feb 7;5(1):8. (PMID: 32296030) |
معلومات مُعتمدة: | RYC-2012-12104 Ministerio de Ciencia, Innovación y Universidades; n/a Fero Foundation; GC16173694BARB Fundación Científica Asociación Española Contra el Cáncer; PI18/00757 Instituto de Salud Carlos III; SAF2016-75991-R Ministerio de Ciencia, Innovación y Universidades |
فهرسة مساهمة: | Keywords: PP2; SRC kinases; cancer stem cells; dasatinib; pancreatic ductal adenocarcinoma; patient-derived xenografts |
تواريخ الأحداث: | Date Created: 20201014 Date Completed: 20210226 Latest Revision: 20210226 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC7588004 |
DOI: | 10.3390/ijms21207437 |
PMID: | 33050159 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1422-0067 |
---|---|
DOI: | 10.3390/ijms21207437 |